Technology & Patents

Technology

MiReven’s technology is based on the pioneering discoveries made by Prof. Peter Leedman, MB BS, FRACP, PhD, and Dr Keith Giles, PhD in their laboratory at the Harry Perkins Institute of Medical Research. Leedman, Giles et al. have developed a compelling body of preclinical data supporting the potential of miR-7 to suppress tumour growth, particularly in the many cancers known to be controlled by an essential growth receptor for cancer, known as the epidermal growth factor receptor (EGFR). The Perkins Institute’s published research shows that miR-7 can knock-out EGFR, with the additional potential to inhibit multiple EGFR signalling pathways that promote cancer development. EGFR is a major target for cancer therapy because it is often associated with disease progression, resistance to chemotherapy and radiation therapy.

Webster, Price, Zhang, Mattick & Leedman (2009): Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7. Journal of Biological Chemistry 284, 5731-5741

Intellectual Property

MiReven holds worldwide exclusive rights to the UWA miR-7 patents, creating a solid IP portfolio protecting the commercialisation of miR-7 as an anti-cancer therapeutic.

Our patent estate includes 4 patent families to date, 3 of which are published and have entered National Phase examination in multiple jurisdictions including the US and Europe.

Patent families include:

  • Method of modulation of expression of EGFR involving miRNA
  • Methods and composition for increasing sensitivity to tyrosine kinase inhibitors
  • Modulation of EGFR ligands

Patent Applications

WO 2008/025073 A1
METHOD OF MODULATION OF EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INVOLVING MIRNA  Full PDF

Applicants/Inventors  LEEDMAN, Peter;  GILES, Keith;  WEBSTER, Rebecca
Applicants  THE UNIVERSITY OF WESTERN AUSTRALIA, Nedlands, Western Australia 6907 (AU)
Filing Date  Aug 28, 2007
Publication Date  Mar 6, 2008
Agents  GRIFFITH HACK, 109 St Georges Terrace, Perth, W.A. 6000 (AU)
Application Number  AU2007/001247
Priority
AU Aug 28, 2006 2006904662
AU Feb 6, 2007 2007900558

Abstract
The present invention relates to a method for modulating the expression of epidermal growth factor receptor (EGFR) and its downstream signalling effectors. In particular, the present invention relates to a method for modulating the expression of epidermal growth factor receptor (EGFR) or like molecule in a cell comprising contacting said cell with an agent capable of directly or indirectly interacting with the 3 ‘ -untranslated region (UTR) of the mRNA of said EGFR or like molecule, wherein the UTR is encoded by a sequence which comprises a sequence having at least about 70% identity with at least one sequence selected from the group consisting of the sequences set forth in SEQ ID NOs: 1-36.

WO 2011/063455 A1
MODULATION OF EPIDERMAL GROWTH FACTOR RECEPTOR LIGANDS  Full PDF

Applicants/Inventors  LEEDMAN, Peter;  GILES, Keith;  KALINOWSKI, Felicity
Applicants  THE UNIVERSITY OF WESTERN AUSTRALIA, Nedlands, Western Australia 6907 (AU)
Filing Date  Nov 24, 2010
Publication Date  Jun 3, 2011
Agents  RECCHIA, Gavin, Dean et al., Davies Collison Cave, Level 14, 255 Elizabeth Street, Sydney, New South Wales 2000 (AU)
Application Number  AU2010/001577
Priority
AU Nov 24, 2009 2009905758

Abstract
The present invention relates to a method for modulating the expression and/or activity of an epidermal growth factor receptor (EGFR) ligand in a cell or tissue, the method comprising contacting the cell or tissue with a miR-7 miRNA, a precursor or variant thereof, a miRNA comprising a seed region comprising the sequence GGAAGA, or an antagonist of any such miRNA.

WO 2011/063456 A1
METHODS AND COMPOSITIONS FOR INCREASING SENSITIVITY TO TYROSINE KINASE INHIBITORS  Full PDF

Applicants/Inventors  LEEDMAN, Peter;  GILES, Keith;  KALINOWSKI, Felicity
Applicants  THE UNIVERSITY OF WESTERN AUSTRALIA, Nedlands, Western Australia 6907 (AU)
Filing Date  Nov 24, 2010
Publication Date  Jun 3, 2011
Agents  RECCHIA, Gavin, Dean et al., Davies Collison Cave, Level 14, 255 Elizabeth Street, Sydney, NSW 2000 (AU)
Application Number  AU2010/001578
Priority
AU Nov 24, 2009 2009905758

Abstract
The present invention relates to a method for sensitizing a disease cell expressing the epidermal growth factor receptor (EGFR) to a tyrosine kinase inhibitor selective or specific for EGFR and/or its signalling pathway, the method comprising contacting the cell with a miR-7 miRNA, a precursor or variant thereof, or a miRNA comprising a seed region comprising the sequence GGAAGA.